CareLit · DOI-Nachweis · Senologie - Zeitschrift für Mammadiagnostik und -therapie
Combination therapy with Ixabepilone Plus Capecitabine is effective in ER/PR/HER2-negative breast cancer resistant to Anthracyclines and Taxanes
DOI 10.1055/s-0028-1096079
Bibliografische Angaben
Nachweis in CareLit
Autor:innenH Rugol, M Piontek, I Reeb, E Thomas, R Lee, L Fine, R Peck, M Verrill, H Roché
ZeitschriftSenologie - Zeitschrift für Mammadiagnostik und -therapie
Ausgabe09/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: ER/PR/HER2-negative BC patients have fewer treatment options than those with receptor-positive tumors. Ixabepilone showed activity in phase 2 studies of anthracycline- and taxane-pretreated metastatic breast cancer (MBC), including ER/PR/HER2-negative disease. Methods: In 752 patients with anthracycline/taxane-resistant MBC, ixabepilone, 40mg/m2 IV over 3h q3wk, in combination with capecitabine, 2000mg…
Zitieren
Zitierempfehlung
H Rugol, M Piontek, I Reeb, E Thomas, R Lee, L Fine, R Peck, M Verrill, H Roché (2008) Combination therapy with Ixabepilone Plus Capecitabine is effective in ER/PR/HER2-negative breast cancer resistant to Anthracyclines and Taxanes. Senologie - Zeitschrift für Mammadiagnostik und -therapie (09). https://doi.org/10.1055/s-0028-1096079
Mit CareLit weiterarbeiten